IONS

SEC source: 0000874015-19-000095 · edgar.xml · nonDerivative · entry 2

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-19-000095 · edgar.xml · nonDerivative · entry 1

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.

SEC source: 0000874015-19-000093 · edgar.xml · derivative · entry 10

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2029-06-30

F5 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019.

F5 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 1, 2020. The option shall be fully vested and exercisable on July 1, 2023. The option is exercisable to 0 shares on July 1, 2019.

SEC source: 0000874015-19-000093 · edgar.xml · derivative · entry 9

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,110

Underlying: Common Stock · 7,110 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019.

F4 · derivative.expiration_date: Grant of July 1, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 1, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 1, 2023. The RSU is vested as to 0 shares on July 1, 2019.

SEC source: 0000874015-19-000093 · edgar.xml · derivative · entry 6

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 666

Underlying: Common Stock · 667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-19-000093 · edgar.xml · derivative · entry 5

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-19-000093 · edgar.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph H. Wender Trust

Disclosed balance after: 60,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. These shares were issued to the Joseph H. Wender Trust.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. These shares were issued to the Joseph H. Wender Trust.

SEC source: 0000874015-19-000093 · edgar.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Joseph H. Wender Trust

Disclosed balance after: 59,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. These shares were issued to the Joseph H. Wender Trust.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. These shares were issued to the Joseph H. Wender Trust.

SEC source: 0000874015-19-000079 · edgar.xml · derivative · entry 6

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2019-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000079 · edgar.xml · nonDerivative · entry 4

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,094

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.16, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-19-000079 · edgar.xml · nonDerivative · entry 3

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,784

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

SEC source: 0000874015-19-000079 · edgar.xml · nonDerivative · entry 2

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,094

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.68 to $63.68, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000079 · edgar.xml · nonDerivative · entry 1

BERTHELSEN SPENCER R · CIK 0001181548 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2019. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 3/1/2019.

SEC source: 0000874015-19-000075 · edgar.xml · derivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2029-06-09

F1 · derivative.exercise_date: Grant of June 10, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on June 10, 2020. The option shall be fully vested and exercisable on June 10, 2023. The option is exercisable to 0 shares on June 10, 2019.

F1 · derivative.expiration_date: Grant of June 10, 2019 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on June 10, 2020. The option shall be fully vested and exercisable on June 10, 2023. The option is exercisable to 0 shares on June 10, 2019.

SEC source: 0000874015-19-000077 · edgar.xml · derivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,221

Underlying: Common Stock · 14,221 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F2 · derivative.exercise_date: Grant of June 10, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on June 10, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on June 10, 2023. The RSU is vested as to 0 shares on June 10, 2019.

F2 · derivative.expiration_date: Grant of June 10, 2019 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on June 10, 2020. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on June 10, 2023. The RSU is vested as to 0 shares on June 10, 2019.

SEC source: 0000874015-19-000070 · edgar.xml · derivative · entry 4

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2019-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000070 · edgar.xml · nonDerivative · entry 2

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,794

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.05 to $65.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000070 · edgar.xml · nonDerivative · entry 1

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

SEC source: 0000874015-19-000065 · edgar.xml · derivative · entry 4

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,000 shares

Expires 2026-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000065 · edgar.xml · nonDerivative · entry 2

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,794

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.60 to $72.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000065 · edgar.xml · nonDerivative · entry 1

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019.

SEC source: 0000874015-19-000063 · edgar.xml · derivative · entry 3

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 50,000 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000063 · edgar.xml · nonDerivative · entry 2

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,677

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/26/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/26/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.11, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-19-000063 · edgar.xml · nonDerivative · entry 1

PARSHALL B LYNNE · CIK 0001073385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,677

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/26/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/26/2019.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 19

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 2,500

Underlying: Common Stock · 700 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 18

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 0

Underlying: Common Stock · 300 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 17

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,180

Underlying: Common Stock · 13,320 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 16

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,680 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 12

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,532

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 11

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 6,232

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 10

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,532

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 9

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,832

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,634

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.50 to $84.75, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,954

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,634

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 5

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 15

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 300

Underlying: Common Stock · 1,000 shares

Expires 2020-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · derivative · entry 14

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,680

Underlying: Common Stock · 10,000 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 5,532

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 6,532

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,634

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

SEC source: 0000874015-19-000061 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,634

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/13/2019.

SEC source: 0000874015-19-000059 · edgar.xml · derivative · entry 9

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 20,000 shares

Expires 2021-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000059 · edgar.xml · derivative · entry 8

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 2,240 shares

Expires 2020-01-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000059 · edgar.xml · derivative · entry 7

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,439

Underlying: Common Stock · 24,000 shares

Expires 2024-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-19-000059 · edgar.xml · nonDerivative · entry 6

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,442

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

SEC source: 0000874015-19-000059 · edgar.xml · nonDerivative · entry 5

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,442

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

SEC source: 0000874015-19-000059 · edgar.xml · nonDerivative · entry 4

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,442

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

SEC source: 0000874015-19-000059 · edgar.xml · nonDerivative · entry 3

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

SEC source: 0000874015-19-000059 · edgar.xml · nonDerivative · entry 2

Geary Richard S · CIK 0001442730 · SVP, Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,442

F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 3/7/2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.67, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.